ClinicalTrials.gg
CompletedNCT01890122Updated Nov 28, 2016Results posted

Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes

A Phase 3 interventional study of Alogliptin and Metformin HCl in Diabetes Mellitus, sponsored by Takeda. Completed at 45 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
647
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies testing alogliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus.

Enrollment
6th of 25
647 · median 438
Started
2013
the only one that year
Phase 3
15 of 25
none open now
Registered
25th of 25
by date
Lead sponsor
25 of 25
Takeda

Among the 25 studies testing alogliptin in Diabetes Mellitus, this one is the 6th largest by enrollment, is the only one that started in 2013, is one of 15 in phase 3, and was the 25th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 25 studies testing alogliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About alogliptin

alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies testing alogliptin in Diabetes Mellitus as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of alogliptin and metformin fixed-dose combination (FDC) as compared with alogliptin alone or metformin alone on Type 2 Diabetes Mellitus (T2DM).

Read the detailed description

The drug being tested in this study is a fixed-dose combination tablet of alogliptin and metformin to treat people who have diabetes. This study will look at glycemic control in people who take alogliptin and metformin FDC compared with alogliptin or metformin alone. The study will enroll approximately 640 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Alogliptin 12.5 mg twice daily (BID)
  • Metformin hydrochloride (HCl) 500 mg BID
  • Alogliptin 12.5 mg and Metformin HCl 500 mg FDC BID
  • Placebo (dummy inactive pill) - this is a tablet/capsule that looks like the study drug but has no active ingredient.

All participants will be asked to take 2 tablets and 1 capsule twice a day at the same time each day throughout the study. All participants will be asked to record any hypoglycemic events in a diary. This multi-center trial will be conducted in China, South Korea, Taiwan and Malaysia. The overall time to participate in this study is 34 weeks. Participants will make 11 visits to the clinic.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has a historical diagnosis of Type 2 diabetes mellitus (T2DM).
  4. Male or female and aged 18 to 75 years, inclusive.
  5. (BMI) between 20 and 45 kg/m\^2, inclusive.
  6. A female of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent throughout the duration of the study.
  7. Is experiencing inadequate glycemic control defined as glycosylated () concentration between 7.5% and 10%, inclusive, and has been treated with diet and exercise for at least 2 months prior to Screening. (Exception: a participant who has received any other diabetic therapy for less than 7 days in total within the 2 months prior to the screening, can be included).
  8. If male, has a hemoglobin >12 g/dL (>120 g/L) at Screening or if female, has a hemoglobin >10 g/dL (>100 g/L) at Screening.
  9. If male, has a serum creatinine \<1.5 mg/dL at Screening or if female, has a serum creatinine \<1.4 mg/dL at Screening, and estimated (eGFR) >60 mL/min/1.73 m\^2 based on calculation using the Modification of Diet in Renal Disease (MDRD) at Screening.
  10. Willing and able to monitor their own blood glucose concentrations using a home glucose monitor and complete a subject diary.

Exclusion criteria

Exclusion Criteria:

  1. Participated in another clinical study within 90 days prior to Screening.
  2. Received any compound within 30 days prior to Randomization.
  3. Received a dipeptidyl peptidase-4 (DPP-4) inhibitor within 3 months prior to screening.
  4. History of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
  5. History of treatment for diabetic gastric paresis, gastric banding, or gastric bypass surgery.
  6. History of diabetic ketoacidosis or hyperosmolar non-ketotic coma.
  7. Chronic pancreatitis and/or history of acute pancreatitis.
  8. Systolic blood pressure >180 mm Hg and/or diastolic blood pressure >110 mm Hg at Screening.
  9. History of any hemoglobinopathy or diagnosis of chronic anemia.
  10. Class III or IV heart failure. (Participants who are stable at Class I or II and are currently treated, are candidates for the study.)
  11. History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.
  12. History of any cancer, other than squamous cell or basal cell carcinoma of the skin, which has not been in full remission for at least 5 years prior to Screening. Participants with a history of treated cervical intraepithelial neoplasia [CIN] I or CIN II are allowed.
  13. Significant clinical sign or symptom of hepatopathy, acute or chronic hepatitis, or (ALT) is 2.5 times above value.
  14. History of angioedema in association with use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB).
  15. History of or allergies to any DPP-4 inhibitor and/or metformin or related compounds.
  16. Has used oral or systemically injected (including intra-articular injection) or has used weight-loss drugs within 2 months prior to Screening. (Inhaled or topical corticosteroids were allowed.)
  17. History of alcohol or substance abuse within 2 years prior to Screening.
  18. Has used medicine for weight loss within 60 days prior to Screening (such as Xenical, Sibutramine, Phenylpropanolamine or similar nonprescription drugs).
  19. History of organ transplantation.
  20. Is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  21. Has, in the judgment of the investigator, any major illness or debility that may prohibit the participant from completing the study.
  22. If female, is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
647 participants (actual)

Study arms

  • Active comparator
    Metformin HCl 500 mg

    Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.

    Drug: Metformin HCl · Drug: Alogliptin Placebo · Drug: Alogliptin and Metformin FDC Placebo

  • Active comparator
    Alogliptin 12.5 mg

    Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.

    Drug: Alogliptin · Drug: Metformin Placebo · Drug: Alogliptin and Metformin FDC Placebo

  • Experimental
    Alogliptin 12.5 mg + Metformin HCl 500 mg FDC

    Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.

    Drug: Alogliptin and Metformin Fixed-Dose Combination (FDC) · Drug: Alogliptin Placebo · Drug: Metformin Placebo

  • Placebo comparator
    Placebo

    Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.

    Drug: Alogliptin Placebo · Drug: Metformin Placebo · Drug: Alogliptin and Metformin FDC Placebo

Interventions

  • Alogliptin tablets

    Also known as: SYR-322; Nesina

  • Metformin HCl capsules

    Also known as: Glucophage

  • DrugAlogliptin and Metformin Fixed-Dose Combination (FDC)

    Drug pages: Alogliptin · Metformin

    Alogliptin and metformin FDC tablets

    Also known as: Kazano

  • DrugAlogliptin Placebo

    Alogliptin placebo-matching tablets

  • DrugMetformin Placebo

    Metformin placebo-matching capsules

  • DrugAlogliptin and Metformin FDC Placebo

    Alogliptin and metformin FDC placebo-matching tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination)

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 26 or early termination relative to baseline. Negative change indicates better glycemic control.

    Time frame: Baseline and Week 26 (or Early termination)

Secondary outcomes

  1. Change From Baseline in HbA1c at Weeks 4, 8, 12, 16 and 20

    The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Weeks 4, 8, 12, 16 and 20 relative to baseline. Negative change indicates better glycemic control.

    Time frame: Baseline and Weeks 4, 8, 12, 16 and 20

  2. Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 8, 12, 16, 20 and 26

    The change between the FPG value collected at Weeks 4, 8, 12, 16, 20 and 26 relative to baseline. Negative change indicates better glycemic control.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26

  3. Time to Hyperglycemic Rescue Event

    Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After \>1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline. Time to hyperglycemic rescue was censored if the participant did not experience a hyperglycemic rescue event.

    Time frame: From the date of randomization through Week 26

  4. Percentage of Participants Requiring Hyperglycemic Rescue

    Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After \>1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline.

    Time frame: Baseline up to Week 26

  5. Percentage of Participants With Marked Hyperglycemia

    Marked hyperglycemia is defined as FPG level ≥200 mg/dL (11.1 mmol/L).

    Time frame: Baseline up to Week 26

  6. Change From Baseline in Body Weight at Weeks 12 and 26

    Change in participant's body weight at Weeks 12 and 26 relative to baseline.

    Time frame: Baseline and Weeks 12 and 26

  7. Percentage of Participants With Glycosylated Hemoglobin ≤6.5%

    Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤6.5%.

    Time frame: Week 26

  8. Percentage of Participants With Glycosylated Hemoglobin ≤7.0%

    Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7%.

    Time frame: Week 26

  9. Percentage of Participants With Glycosylated Hemoglobin ≤7.5%

    Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7.5%.

    Time frame: Week 26

  10. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥0.5%

    Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥0.5%.

    Time frame: Baseline and Week 26

  11. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.0%

    Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.0%.

    Time frame: Baseline and Week 26

  12. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.5%

    Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.5%.

    Time frame: Baseline and Week 26

  13. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%

    Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥2.0%.

    Time frame: Baseline and Week 26

07

Results

Posted Nov 28, 2016

Participant flow

Participants took part in the study at 59 investigative sites in China, Malaysia, South Korea and Taiwan from 26 August 2013 to 05 October 2015.

Participant flow — Overall Study
MilestoneMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Started162163159163
Treated161162159163
Completed135126146104
Not completed27371359
Withdrew: Adverse event1112
Withdrew: Major protocol deviation3101
Withdrew: Lost to follow-up0122
Withdrew: Voluntary withdrawal88211
Withdrew: Lack of efficacy1424741
Withdrew: Reason not specified0112
Withdrew: Randomized but not treated1100

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination)

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 26 or early termination relative to baseline. Negative change indicates better glycemic control.

Time frame:
Baseline and Week 26 (or Early termination)
Reported as:
Mean · percentage of glycosylated hemoglobin
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination)
percentage of glycosylated hemoglobinMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination)-0.32 ± 1.067-1.23 ± 0.877-1.06 ± 0.970-1.72 ± 1.024
Statistical analysis
  • Metformin HCl 500 mg vs Alogliptin 12.5 mg + Metformin HCl 500 mg FDC · ANCOVA · p = < 0.0001 (An analysis of covariance (ANCOVA) model was used with treatment and country as fixed effects, and Baseline HbA1c as a continuous covariate.) · Least square mean difference: -0.49 · 95% CI -0.700 to -0.278
  • Alogliptin 12.5 mg vs Alogliptin 12.5 mg + Metformin HCl 500 mg FDC · ANCOVA · p = < 0.0001 (An ANCOVA model was used with treatment and country as fixed effects, and Baseline HbA1c as a continuous covariate.) · Least square mean difference: -0.68 · 95% CI -0.889 to -0.467
SecondaryChange From Baseline in HbA1c at Weeks 4, 8, 12, 16 and 20

The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Weeks 4, 8, 12, 16 and 20 relative to baseline. Negative change indicates better glycemic control.

Time frame:
Baseline and Weeks 4, 8, 12, 16 and 20
Reported as:
Mean · percentage of glycosylated hemoglobin
Change From Baseline in HbA1c at Weeks 4, 8, 12, 16 and 20
percentage of glycosylated hemoglobinMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Week 4 (n=157,156,154,156)-0.57 ± 0.483-0.41 ± 0.570-0.80 ± 0.489-0.18 ± 0.503
Week 8 (n=160,160,158,157)-0.90 ± 0.682-0.78 ± 0.756-1.29 ± 0.732-0.29 ± 0.738
Week 12 (n=160,160,158,157)-1.06 ± 0.793-1.01 ± 0.839-1.57 ± 0.873-0.27 ± 0.895
Week 16 (n=160,160,158,157)-1.18 ± 0.816-1.06 ± 0.900-1.71 ± 0.937-0.33 ± 0.957
Week 20 (n=160.160,158,157)-1.24 ± 0.852-1.11 ± 0.925-1.74 ± 0.969-0.33 ± 1.006
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 8, 12, 16, 20 and 26

The change between the FPG value collected at Weeks 4, 8, 12, 16, 20 and 26 relative to baseline. Negative change indicates better glycemic control.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 8, 12, 16, 20 and 26
mg/dLMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Week 4 (n=157,154,155,156)-1.42 ± 1.344-1.01 ± 1.794-2.01 ± 2.1570.02 ± 1.532
Week 8 (n=160,158,158,157)-1.50 ± 1.571-1.17 ± 1.788-2.13 ± 1.808-0.08 ± 1.682
Week 12 (n=160,158,158,157)-1.48 ± 1.527-1.33 ± 1.938-2.14 ± 1.779-0.08 ± 2.112
Week 16 (n=160,158,158,157)-1.62 ± 1.599-1.25 ± 2.148-2.17 ± 1.923-0.07 ± 2.020
Week 20 (n=160,158,158,157)-1.57 ± 1.634-1.19 ± 2.248-2.26 ± 1.995-0.12 ± 2.092
Week 26 (n=160,158,158,157)-1.45 ± 1.674-1.06 ± 2.307-2.06 ± 2.274-0.04 ± 2.060
SecondaryTime to Hyperglycemic Rescue Event

Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After \>1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline. Time to hyperglycemic rescue was censored if the participant did not experience a hyperglycemic rescue event.

Time frame:
From the date of randomization through Week 26
Reported as:
Median · days
Time to Hyperglycemic Rescue Event
daysMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Time to Hyperglycemic Rescue EventNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (113.0 to NA)
SecondaryPercentage of Participants Requiring Hyperglycemic Rescue

Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After \>1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline.

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Hyperglycemic Rescue
percentage of participantsMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Percentage of Participants Requiring Hyperglycemic Rescue8.714.84.425.5
SecondaryPercentage of Participants With Marked Hyperglycemia

Marked hyperglycemia is defined as FPG level ≥200 mg/dL (11.1 mmol/L).

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Marked Hyperglycemia
percentage of participantsMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Percentage of Participants With Marked Hyperglycemia8.812.75.715.9
SecondaryChange From Baseline in Body Weight at Weeks 12 and 26

Change in participant's body weight at Weeks 12 and 26 relative to baseline.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Median · kg
Change From Baseline in Body Weight at Weeks 12 and 26
kgMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Week 12 (n=153,151,149,145)-0.71 ± 1.735-0.19 ± 1.696-0.14 ± 1.730-0.32 ± 1.837
Week 26 (n=156,156,156,152)-0.93 ± 2.240-0.22 ± 2.291-0.57 ± 2.336-0.33 ± 2.220
SecondaryPercentage of Participants With Glycosylated Hemoglobin ≤6.5%

Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤6.5%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin ≤6.5%
percentage of participantsMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Percentage of Participants With Glycosylated Hemoglobin ≤6.5%27.321.655.111.8
SecondaryPercentage of Participants With Glycosylated Hemoglobin ≤7.0%

Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin ≤7.0%
percentage of participantsMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Percentage of Participants With Glycosylated Hemoglobin ≤7.0%55.944.477.230.4
SecondaryPercentage of Participants With Glycosylated Hemoglobin ≤7.5%

Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7.5%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin ≤7.5%
percentage of participantsMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Percentage of Participants With Glycosylated Hemoglobin ≤7.5%73.360.584.846.0
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥0.5%

Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥0.5%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥0.5%
percentage of participantsMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥0.5%81.474.189.242.9
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.0%

Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.0%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.0%
percentage of participantsMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.0%63.453.783.525.5
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.5%

Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.5%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.5%
percentage of participantsMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.5%37.336.462.014.9
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%

Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥2.0%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%
percentage of participantsMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%17.417.334.86.2

Adverse events

Collected over Week 1 up to Week 28. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metformin HCl 500 mg—5/161 (3.1%)33/161 (20.5%)
Alogliptin 12.5 mg—4/162 (2.5%)26/162 (16%)
Alogliptin 12.5 mg + Metformin HCl 500 mg FDC—4/158 (2.5%)25/158 (15.8%)
Placebo—5/161 (3.1%)35/161 (21.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Angina unstableCardiac disorders0/1611/1621/1580/161
Prinzmetal anginaCardiac disorders0/1610/1621/1580/161
Umbilical herniaGastrointestinal disorders0/1610/1621/1580/161
Road traffic accidentInjury, poisoning and procedural complications0/1610/1621/1580/161
Bone cystMusculoskeletal and connective tissue disorders0/1610/1621/1580/161
Angina pectorisCardiac disorders0/1610/1620/1581/161
Supraventricular tachycardiaCardiac disorders1/1610/1620/1580/161
VertigoEar and labyrinth disorders1/1610/1620/1580/161
Chest discomfortGeneral disorders1/1610/1620/1580/161
GastroenteritisInfections and infestations1/1610/1620/1581/161
Most frequent other events
Most frequent other events
EventMetformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlacebo
Upper respiratory tract infectionInfections and infestations11/1618/1628/1589/161
HyperlipidaemiaMetabolism and nutrition disorders6/1619/1627/15810/161
Protein urine presentInvestigations5/1612/1627/1586/161
NasopharyngitisInfections and infestations6/1613/1622/1586/161
DiarrhoeaGastrointestinal disorders5/1614/1621/1584/161

Baseline characteristics

Randomized set consisted of all enrolled participants who were randomized.

Age, Continuous
Age, Continuous(years)Metformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlaceboTotal
Mean53.6 ± 9.9155.4 ± 9.6253.4 ± 10.4652.2 ± 10.1753.6 ± 10.08
Sex: Female, Male
Sex: Female, Male(Participants)Metformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlaceboTotal
Female80656868281
Male82989195366
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Metformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlaceboTotal
American Indian or Alaskan Native01023
Asian161162159161643
Multiracial10001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Metformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlaceboTotal
Hispanic or Latino (Yes)00101
Hispanic or Latino (No)162163158163646
Height
Height(cm)Metformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlaceboTotal
Mean163.8 ± 8.72165.0 ± 8.06164.3 ± 7.66164.2 ± 9.19164.3 ± 8.42
Weight
Weight(kg)Metformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlaceboTotal
Mean70.79 ± 12.35771.21 ± 11.66970.73 ± 11.48971.79 ± 13.94971.13 ± 12.388
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Metformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlaceboTotal
Mean26.30 ± 3.56626.16 ± 3.92326.16 ± 3.50826.56 ± 4.21826.30 ± 3.811
Smoking Classification
Smoking Classification(participants)Metformin HCl 500 mgAlogliptin 12.5 mgAlogliptin 12.5 mg + Metformin HCl 500 mg FDCPlaceboTotal
Has Never Smoked125112113112462
Is a Current Smoker27353836136
Is an Ex-smoker101681549

2 further baseline measures are reported on the registry.

08

Study locations

45 sites
  • Beijing, Beijing, China
  • Fuzhou, Fujian, China
  • Xiamen, Fujian, China
  • Guangzhou, Guangdong, China
  • Nanning, Guangxi, China
  • Guiyang, Guizhou, China
  • Hengshui, Hebei, China
  • Shijiazhuang, Hebei, China
  • Shiyan, Hubei, China
  • Wuhan, Hubei, China
  • Changsha, Hunan, China
  • Yueyang, Hunan, China
  • Changzhou, Jiangsu, China
  • Nanjing, Jiangsu, China
  • Suzhou, Jiangsu, China
  • Nanchang, Jiangxi, China
  • Changchun, Jilin, China
  • Shenyang, Liaoning, China
  • Xi'an, Shanxi, China
  • Chengdu, Sichuan, China
  • Wenzhou, Zhejiang, China
  • Beijing, China
  • Shanghai, China
  • Tianjin, China
  • Goyang-si, Gyeonggi-do, Korea, Republic of
  • Seongnam-si, Gyeonggi-do, Korea, Republic of
  • Suwon, Gyeonggi-do, Korea, Republic of
  • Busan, Korea, Republic of
  • Seoul, Korea, Republic of
  • Johor Bahru, Johor, Malaysia
  • Alor Setar, Kedah Darul Aman, Malaysia
  • Alor Setar, Kedah, Malaysia
  • Kubang Kerian, Kelantan, Malaysia
  • Nilai, Negeri Sembilan, Malaysia
  • Seremban, Negeri Sembilan, Malaysia
  • Tampin, Negeri Sembilan, Malaysia
  • Bagan Serai, Perak, Malaysia
  • Ipoh, Perak, Malaysia
  • Petaling Jaya, Selangor, Malaysia
  • Shah Alam, Selangor, Malaysia
  • Putrajaya, WIlayah Persekutuan, Malaysia
  • Kaohsiung, Taiwan
  • New Taipei City, Taiwan
  • Taichung, Taiwan
  • Taipei, Taiwan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Sep 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jul 1, 2013
Start
Sep 2013
Primary completionActual
Sep 2015
CompletionActual
Oct 2015
Results first posted
Nov 28, 2016
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01890122
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 1, 2013
Start date
Sep 2013
Primary completion
Sep 2015
Completion
Oct 2015
Results posted
Nov 28, 2016
Last update
Nov 28, 2016

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alogliptin · Metformin

Start the discussion